ANTIMYELIN ANTIBODIES AS A PREDICTOR OF CLINICALLY DEFINITE MULTIPLE SCLEROSIS AFTER A FIRST DEMYELINATING EVENT
Gespeichert in:
BERGER, T., ET AL., ANTIMYELIN ANTIBODIES AS A PREDICTOR OF CLINICALLY DEFINITE MULTIPLE SCLEROSIS AFTER A FIRST DEMYELINATING EVENT. NEW ENGLAND JOURNAL OF MEDICINE, THE, Vol. 349, no. 2 (2003), p. 139-145.
Ref.
78035
Standort:
SIIS Archivo
Palabras clave:
Detección, Discapacidad física y orgánica, Esclerosis múltiple, Tipología
Detección, Discapacidad física y orgánica, Esclerosis múltiple, Tipología
Ähnliche Einträge: ANTIMYELIN ANTIBODIES AS A PREDICTOR OF CLINICALLY DEFINITE MULTIPLE SCLEROSIS AFTER A FIRST DEMYELINATING EVENT
- INFORMAL CAREGIVING IN MULTIPLE SCLEROSIS PATIENTS: DATA FROM THE MADRID DEMYELINATING DISEASE GROUP STUDY
- SMOKING IS A RISK FACTOR FOR EARLY CONVERSION TO CLINICALLY DEFINITE MULTIPLE SCLEROSIS
- OPTIC NEURITIS IN CHILDREN AND ITS RELATIOSHIP TO MULTIPLE SCLEROSIS: A CLINICAL STUDY OF 21 CHILDREN
- ASPECTOS EMOCIONALES DE LA ESCLEROSIS MULTIPLE:TRADUCCION DEL FOLLETO DE LA NATIONAL MULTIPLE SCLEROSIS SOCIETY
- CLINICAL PRACTICE IMPROVEMENT APPROACH IN MULTIPLE SCLEROSIS REHABILITATION: A PILOT STUDY
- VALUE OF VISUAL EVOKED RESPONSE AND OLIGOCLONAL BANDS IN CEREBROSPINAL FLUID IN DIAGNOSIS OF SPINAL MULTIPLE SCLEROSIS